Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: November 30, 2022 Report Code: GDGMDHC22408IDB-ST

Select Item

Huntington Disease Pipeline Drugs Market Overview

Huntington’s disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

The Huntington Disease pipeline drugs market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and latest news and press releases. Additionally, the report also provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.

Huntington Disease Pipeline Drugs Market Segmentation by Targets

The key targets in the Huntington Disease pipeline drugs market are Huntingtin, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor NMDA Type Subunit, Nuclear Factor Erythroid 2 Related Factor 2, Synaptic Vesicular Amine Transporter, Alpha 1 Adrenergic Receptor, Beta 1 Adrenergic Receptor, C5a Anaphylatoxin Chemotactic Receptor 1, and Caspase 6, among others. Huntingtin is the leading target in the pipeline products market.

Huntington Disease Pipeline Drugs Market Analysis by Targets

Huntington Disease Pipeline Products Market Analysis by Targets

For more target insights into the Huntington Disease pipeline drugs market, download a free report sample

Huntington Disease Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Huntington Disease pipeline products market are Huntingtin Inhibitor, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Synaptic Vesicular Amine Transporter Inhibitor, Alpha 1 Adrenergic Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Caspase 6 Inhibitor, and D2 Dopamine Receptor Antagonist, among others. Huntingtin Inhibitor is the leading mechanism of action in the pipeline.

Huntington Disease Pipeline Products Market Analysis by Mechanisms of Action

Huntington Disease Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Huntington Disease pipeline products market, download a free report sample

Huntington Disease Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Huntington Disease pipeline drugs market are oral, intravenous, intrathecal, subcutaneous, buccal, intracerebral, parenteral, intramuscular, ophthalmic, and topical. Most of the pipeline products are administered through the oral route.

Huntington Disease Pipeline Drugs Market Analysis by Routes of Administration

Huntington Disease Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Huntington Disease pipeline drugs market, download a free report sample

Huntington Disease Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Huntington Disease pipeline products market are small molecule, gene therapy, antisense oligonucleotide, cell therapy, synthetic peptide, monoclonal antibody, oligonucleotide, peptide, antisense RNAi oligonucleotide, and biologic, among others. Small molecule is the leading molecule type in the market.

Huntington Disease Pipeline Products Market Analysis by Molecule Types

Huntington Disease Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Huntington Disease pipeline products market, download a free report sample

Huntington Disease Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Huntington Disease pipeline products market are Medesis Pharma SA, AFFiRiS AG, Anima Biotech Inc, Luye Pharma Group Ltd, MMJ International Holdings Corp, Origami Therapeutics Inc, Prous Institute for Biomedical Research SA, Retrotope Inc, SOLA Biosciences LLC, and SOM Biotech SL. Medesis Pharma SA is the leading company in the pipeline products market.

Huntington Disease Pipeline Products Market Analysis by Companies

Huntington Disease Pipeline Products Market Analysis by CompaniesTo know more about the leading players in the Huntington Disease pipeline products market, download a free report sample

Huntington Disease pipeline Products Market Report Overview

Key Targets Huntingtin, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor NMDA Type Subunit, Nuclear Factor Erythroid 2 Related Factor 2, Synaptic Vesicular Amine Transporter, Alpha 1 Adrenergic Receptor, Beta 1 Adrenergic Receptor, C5a Anaphylatoxin Chemotactic Receptor 1, and Caspase 6
Key Mechanisms of Action Huntingtin Inhibitor, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Synaptic Vesicular Amine Transporter Inhibitor, Alpha 1 Adrenergic Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist, Caspase 6 Inhibitor, and D2 Dopamine Receptor Antagonist
Key Routes of Administration Oral, Intravenous, Intrathecal, Subcutaneous, Buccal, Intracerebral, Parenteral, Intramuscular, Ophthalmic, and Topical
Key Molecule Type Small Molecule, Gene Therapy, Antisense Oligonucleotide, Cell Therapy, Synthetic Peptide, Monoclonal Antibody, Oligonucleotide, Peptide, Antisense RNAi Oligonucleotide, and Biologic
Leading Companies Medesis Pharma SA, AFFiRiS AG, Anima Biotech Inc, Luye Pharma Group Ltd, MMJ International Holdings Corp, Origami Therapeutics Inc, Prous Institute for Biomedical Research SA, Retrotope Inc, SOLA Biosciences LLC, and SOM Biotech SL

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acen Regenerative Medicine Sci-Tech Co Ltd
AFFiRiS AG
Alchemab Therapeutics Ltd
Alkermes Plc
Alnylam Pharmaceuticals Inc
Alsonex Pty Ltd
Anima Biotech Inc
ANLBio Co Ltd
Annexon Inc
Annji Pharmaceutical Co Ltd
AOP Health
ARMGO Pharma Inc
ArunA Bio Inc
Arvinas Inc
Asahi Kasei Pharma Corp
Asdera LLC
Asklepios BioPharmaceutical Inc
Astellas Pharma Inc
Atalanta Therapeutics Inc
Avergen Pharmaceuticals GmbH
Azevan Pharmaceuticals Inc
Berg LLC
Bionaut Labs Inc
Biorchestra Co Ltd
Blade Therapeutics Inc
BrainStorm Cell Therapeutics Inc
Brainvectis SAS
Cellavita Pesquisa Cientifica Ltda
Ceptur Therapeutics Inc
Chaperone Pharma BV
Chaperone Therapeutics Inc
Chong Kun Dang Pharmaceutical Corporation
Cleave Therapeutics Inc
Collaborative Medicinal Development LLC
DanPET AB
Dystrogen Therapeutics SA
Eikonoklastes Therapeutics Inc
Emerald Health Pharmaceuticals Inc
Enzerna Biosciences LLC
Exicure Inc
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Forest Hills Partners Hong Kong Ltd
Fundamental Pharma Gmbh
Gatehouse Bio
Immungenetics AG
Incisive Genetics Inc
InnoMedica Holding AG
Janusq LLC
KeifeRx LLC
Krisani Bio Sciences Pvt Ltd
Locanabio Inc
Loqus23 Therapeutics Ltd
Luye Pharma Group Ltd
Malachite Innovations Inc
Medesis Pharma SA
MindImmune Therapeutics Inc
Mitochon Pharmaceuticals Inc
Mitoconix Bio Ltd
Mitokinin LLC
MitoRx Therapeutics Ltd
MMJ International Holdings Corp
Modelis Inc
NeuBase Therapeutics Inc
NeuExcell Therapeutics Inc
Neurano Bioscience
Neurimmune Holding AG
Neurodon LLC
NeuroNascent Inc
Neuropore Therapies Inc
Nevrox Ltd
New World Laboratories Inc
NLS Pharmaceutics AG
Novartis AG
Nuredis Inc
Ophidion Inc
Origami Therapeutics Inc
Oryzon Genomics SA
Oxalys Pharmaceuticals Inc
Paramag Biosciences
Passage Bio Inc
PCG-Biotech Co Ltd
PharmatrophiX Inc
PolyCore Therapeutics LLC
Priavoid GmbH
Prilenia Therapeutics Development Ltd
Primary Peptides Inc
ProMIS Neurosciences Inc
ProQR Therapeutics NV
Prous Institute for Biomedical Research SA
PTC Therapeutics Inc
PurMinds NeuroPharma Inc
Reata Pharmaceuticals Inc
reMYND NV
ReNeuron Group Plc
Resilio Therapeutics LLC
ResQ Biotech
Retrotope Inc
Sage Therapeutics Inc
Sana Biotechnology Inc
Seelos Therapeutics, Inc.
Seneb BioSciences Inc
Shinkei Therapeutics LLC
SOLA Biosciences LLC
SOM Biotech SL
Sosei Group Corp
Spark Therapeutics Inc
Stealth BioTherapeutics Corp
Suven Life Sciences Ltd
T3D Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Teitur Trophics ApS
Teva Pharmaceutical Industries Ltd
Trailhead Biosystems Inc
TreeFrog Therapeutics SAS
Triplet Therapeutics Inc
Ultragenyx Pharmaceutical Inc
UniQure NV
Vaccinex Inc
Vanqua Bio Inc
Vico Therapeutics BV
Vivoryon Therapeutics NV
Voyager Therapeutics Inc
Vybion Inc
Wave Life Sciences Ltd
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Huntington Disease – Overview

Huntington Disease – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Huntington Disease – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Huntington Disease – Companies Involved in Therapeutics Development

Huntington Disease – Drug Profiles

Huntington Disease – Dormant Projects

Huntington Disease – Discontinued Products

Huntington Disease – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Huntington Disease, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Huntington Disease – Dormant Projects, 2022

Huntington Disease – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Huntington Disease, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Pharmaceuticals
New
Borderline Personality Disorder (BPD) Clinical Trial Analysis by Phase, Trial…
$2,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more